BACKGROUND: The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011. MATERIALS AND METHODS: The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. RESULTS: Current data do not identify distinct etiologic or pathophysiological factors mediating development of FMS. The development of FMS is associated with inflammatory rheumatic diseases (EL2b), with gene polymorphisms of the 5-hydroxytryptamine (HT)(2) receptor (EL3a), lifestyle factors (smoking, obesity, lack of physical activity; EL2b), physical and sexual abuse in childhood and adulthood (EL3a). CONCLUSION: FMS is most likely the result of various pathogenetic factors and pathophysiological mechanisms. The English full-text version of this article is available at SpringerLink (under "Supplemental").
BACKGROUND: The scheduled update to the German S3 guidelines on fibromyalgia syndrome (FMS) by the Association of the Scientific Medical Societies ("Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften", AWMF; registration number 041/004) was planned starting in March 2011. MATERIALS AND METHODS: The development of the guidelines was coordinated by the German Interdisciplinary Association for Pain Therapy ("Deutsche Interdisziplinären Vereinigung für Schmerztherapie", DIVS), 9 scientific medical societies and 2 patient self-help organizations. Eight working groups with a total of 50 members were evenly balanced in terms of gender, medical field, potential conflicts of interest and hierarchical position in the medical and scientific fields. Literature searches were performed using the Medline, PsycInfo, Scopus and Cochrane Library databases (until December 2010). The grading of the strength of the evidence followed the scheme of the Oxford Centre for Evidence-Based Medicine. RESULTS: Current data do not identify distinct etiologic or pathophysiological factors mediating development of FMS. The development of FMS is associated with inflammatory rheumatic diseases (EL2b), with gene polymorphisms of the 5-hydroxytryptamine (HT)(2) receptor (EL3a), lifestyle factors (smoking, obesity, lack of physical activity; EL2b), physical and sexual abuse in childhood and adulthood (EL3a). CONCLUSION: FMS is most likely the result of various pathogenetic factors and pathophysiological mechanisms. The English full-text version of this article is available at SpringerLink (under "Supplemental").
Authors: Winfried Häuser; Maria Kosseva; Nurcan Üceyler; Petra Klose; Claudia Sommer Journal: Arthritis Care Res (Hoboken) Date: 2011-06 Impact factor: 4.794
Authors: Mika Kivimäki; Päivi Leino-Arjas; Marianna Virtanen; Marko Elovainio; Liisa Keltikangas-Järvinen; Sampsa Puttonen; Maarit Vartia; Eric Brunner; Jussi Vahtera Journal: J Psychosom Res Date: 2004-11 Impact factor: 3.006
Authors: Lynne J Hocking; Blair H Smith; Gareth T Jones; David M Reid; David P Strachan; Gary J Macfarlane Journal: Pain Date: 2010-02-18 Impact factor: 6.961
Authors: Dina Dadabhoy; Leslie J Crofford; Michael Spaeth; I Jon Russell; Daniel J Clauw Journal: Arthritis Res Ther Date: 2008-08-08 Impact factor: 5.156
Authors: Brian Walitt; Gerard Urrútia; María Betina Nishishinya; Sarah E Cantrell; Winfried Häuser Journal: Cochrane Database Syst Rev Date: 2015-06-05
Authors: Sheena Derry; Philip J Wiffen; Winfried Häuser; Martin Mücke; Thomas Rudolf Tölle; Rae F Bell; R Andrew Moore Journal: Cochrane Database Syst Rev Date: 2017-03-27
Authors: Winfried Häuser; Eva-Maria Hoffmann; Frederick Wolfe; Angus B Worthing; Neil Stahl; Russell Rothenberg; Brian Walitt Journal: Clin Exp Rheumatol Date: 2015-03-18 Impact factor: 4.473
Authors: N Üçeyler; M Burgmer; E Friedel; W Greiner; F Petzke; M Sarholz; M Schiltenwolf; A Winkelmann; C Sommer; W Häuser Journal: Schmerz Date: 2017-06 Impact factor: 1.107